Effect of the oral hypoglycemic agent pirogliride (McN-3495) on glycogen levels of normal and diabetic rats.
Pirogliride, a new oral hypoglycemic agent unrelated structurally or mechanistically to either the sulfonylureas or biguanides, produced a dose-dependent increase in liver but not muscle glycogen levels of fasted non-diabetic rats and produced at 100 mg/kg, p.o. a modest increase in liver but not gastrocnemius muscle glycogen of fasted streptozotocin diabetic rats. This liver glycogenic effect of pirogliride was similar to that obtained using insulin but differed from the decrease of liver glycogen levels which occurred following acute phenformin treatment.
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D005215:Fasting; D006003:Glycogen / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000187:drug effects*; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D009132:Muscles / Q000187:drug effects* / Q000378:metabolism; D009928:Organ Specificity; D010629:Phenformin / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014044:Tolbutamide / Q000494:pharmacology
D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D011759:Pyrrolidines; C021239:pirogliride; D006003:Glycogen; D014044:Tolbutamide; D010629:Phenformin